Epidemiology and predictors of survival of tongue cancer among Egyptians in the Delta region
In conclusion, population based registries are needed to further quantify the risk of disease in Africa and the Middle East. In addition, high treatment failure after classic treatment of tongue cancer warrants further research in ide ntifying underlying aetiology and implementing neoadjuvant and adjuvant therapy in the treatment tools.
Preclinical/clinical data support neoadjuvant immunotherapy and PD-1/CTLA-4 inhibitor combinations. We hypothesized that a short 3-week neoadjuvant course of nivolumab (N) +/- the CTLA-4 inhibitor ipilimumab (NI) would lead to tumor response and not delay definitive surgery in patients (pts) with resectable oral cavity (OC).
(American Society for Radiation Oncology) A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients. In the randomized trial, two neoadjuvant doses of nivolumab given with or without ipilimumab led to complete or partial tumor shrinkage in most cases and did not delay any patients from continuing on to standard treatment. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.
CONCLUSIONS: Together, these results implicate PD-1 expression by T cells in the mechanism of functional immunodominance among independent T cell clones within a progressing tumor, and support the use of neoadjuvant PD-1 immune checkpoint blockade in patients with surgically resectable carcinomas. PMID: 31645352 [PubMed - as supplied by publisher]
Conclusions: In OSCC, very low preoperative NLR values have a negative prognostic impact on survival and recurrence, similarly to high ratios. ENE and perineural spread are the most important clinical-pathologic prognosticators. Introduction Oral squamous cell carcinoma (OSCC) accounts for more than 95% of oral tumors and is the eighth most frequent cancer worldwide, with an estimated incidence of 640,000 new cases per year (1). Survival of OSCC has slightly improved over the last 30 years, probably as a consequence of multimodal treatment spreading. However, intensified therapeutic regimens can result in signific...
AbstractOral cancers are the most common cancer in India due to tobacco abuse in the form of chewing, smoking, and inhalation. Majority of these patients present late at advanced disease stage. Such patients have significant morbidity irrespective of the intent of treatment; the survival rate is very poor. To improve loco-regional control and survival, neoadjuvant chemotherapy has been started in many centers all over the world. To study the effect of injecting methotrexate as a single agent in (1) down-staging and increasing operability of oral cancers, (2) need for reconstructive surgery, and (3) recurrence. A total of 5...
Abstract PURPOSE: We studied the impact of mTOR signaling inhibition with rapamycin in head and neck squamous cell carcinoma (HNSCC) in the neoadjuvant setting. The goals were to evaluate the mTOR pathway as a therapeutic target for advanced HNSCC patients, and the clinical safety, anti-tumor, and molecular activity of rapamycin administration on HNSCC. EXPERIMENTAL DESIGN: Patients with untreated stage II-IVA HNSCC received rapamycin for 21 days (day 1, 15mg; days 2-12, 5mg) prior to definitive treatment with surgery or chemoradiation. Treatment responses were assessed clinically and radiographically with CT...
Condition: Squamous Cell Carcinoma of the Oral Cavity Interventions: Biological: Nivolumab, Surgery, Radiotherapy; Biological: Nivolumab, Surgery, Chemoradiotherapy Sponsors: The Clatterbridge Cancer Centre NHS Foundation Trust; University of Liverpool; Bristol-Myers Squibb Not yet recruiting